Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study.
An open, randomised study was performed to determine whether two doses of influenza vaccine were more effective than one to elicit an immune response in 70 patients with haematological malignancies. The responses were not improved by two doses compared with one (influenza A virus serotypes H1/N1 18% vs. 22% and H3/N2 26% vs. 14%; influenza B 25% vs. 22%). The results were similar in patients with ongoing and discontinued therapy. Patients treated with monoclonal antibodies for lymphoma had very poor responses. We conclude that two doses of influenza vaccine do not improve the antibody response in patients with haematological malignancies.
Ljungman
Per
P
Haematology Centre, Karolinska University Hospital, Stockholm, Sweden. per.ljungman@medhs.ki.se
Nahi
Hareth
H
Linde
Annika
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000912:Antibodies, Neoplasm / Q000276:immunology; D004334:Drug Administration Schedule; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D008223:Lymphoma / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000628:therapy; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007252:Influenza Vaccines